Biogen Pharmachem Industries (531752) Q4 25/26 earnings summary

Executive summary

• Audited financial results for the quarter and year ended 31st March 2026 were approved by the board on 14th May 2026.

• The board meeting to approve results was held between 4:00 PM and 4:30 PM.

Financial highlights

• Revenue from operations for the year ended 31st March 2026 was ₹255.80 lakhs, up from ₹83.84 lakhs year-over-year.

• Net profit after tax for the year was ₹85.95 lakhs, compared to a net loss of ₹29.27 lakhs in the previous year.

• Total comprehensive income for the year was ₹85.95 lakhs, a significant turnaround from the prior year.

• Paid-up equity share capital increased to ₹9,026.03 lakhs from ₹6,526.03 lakhs year-over-year.

• Other equity decreased to ₹882.68 lakhs from ₹2,666.74 lakhs year-over-year.

Key financial ratios and metrics

• Basic and diluted EPS for the year ended 31st March 2026 was ₹0.01, compared to a loss per share of ₹(0.00) in the previous year.

• Total assets increased to ₹9,939.89 lakhs as of 31st March 2026, up from ₹9,201.77 lakhs as of 31st March 2025.

• Net cash flow from operating activities was ₹156.83 lakhs for the year, up from ₹108.20 lakhs year-over-year.